BIOMAT Database Logo BIOMAT Database Logo

Randomized multicenter trial of adjuvant intraportal chemotherapy for colorectal cancer (SAKK 40/81). An interim report. 1990

U Metzger, and U Laffer, and P Aeberhard, and M Arigoni, and S Arma, and J Barras, and R Egeli, and S Martinoli, and W Mueller, and W Schweizer
University Hospital, Zurich, Switzerland.

A prospective, randomized trial of adjuvant portal infusion of 5-fluorouracil in combination with mitomycin C was conducted on 469 patients with operable colorectal cancer. A single postoperative course of the cytotoxic agents was compared with radical surgery alone. The actuarial 5-year survival (median follow-up 48 months) was 70 +/- 3% in the chemotherapy group and 57 +/- 4% in the control group (p = 0.10). The respective figures for disease-free survival were 62 +/- 4% and 53 +/- 4% (p = 0.09). Among the 195 cases with strict adherence to the protocol for adjuvant chemotherapy there were 59 recurrences and 44 deaths in the follow-up period, whereas in the 274 with no or incomplete chemotherapy there were 120 recurrences and 99 deaths (p less than 0.05). Perioperative adjuvant chemotherapy via portal infusion proved to be feasible in a multicenter setting. Follow-up will be continued, in order to provide definitive information on survival according to randomization.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008937 Mitomycins A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
D011169 Portal Vein A short thick vein formed by union of the superior mesenteric vein and the splenic vein. Portal Veins,Vein, Portal,Veins, Portal
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

U Metzger, and U Laffer, and P Aeberhard, and M Arigoni, and S Arma, and J Barras, and R Egeli, and S Martinoli, and W Mueller, and W Schweizer
[Final results of a randomized clinical trial of adjuvant intraportal chemotherapy for colorectal cancer: Intraportal Chemotherapy for Colorectal Cancer Group].
October 2002, Gan to kagaku ryoho. Cancer & chemotherapy,
U Metzger, and U Laffer, and P Aeberhard, and M Arigoni, and S Arma, and J Barras, and R Egeli, and S Martinoli, and W Mueller, and W Schweizer
Adjuvant intraportal chemotherapy for colorectal cancer.
May 1995, Lancet (London, England),
U Metzger, and U Laffer, and P Aeberhard, and M Arigoni, and S Arma, and J Barras, and R Egeli, and S Martinoli, and W Mueller, and W Schweizer
Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical Cancer Research (SAKK)
February 1995, Lancet (London, England),
U Metzger, and U Laffer, and P Aeberhard, and M Arigoni, and S Arma, and J Barras, and R Egeli, and S Martinoli, and W Mueller, and W Schweizer
Perioperative and adjuvant chemotherapy in colon cancer: results of SAKK trial 40/93.
March 2009, International journal of colorectal disease,
U Metzger, and U Laffer, and P Aeberhard, and M Arigoni, and S Arma, and J Barras, and R Egeli, and S Martinoli, and W Mueller, and W Schweizer
Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Régional d'Etude du Cancer Colo-Rectal (Belgium).
August 2000, Anti-cancer drugs,
U Metzger, and U Laffer, and P Aeberhard, and M Arigoni, and S Arma, and J Barras, and R Egeli, and S Martinoli, and W Mueller, and W Schweizer
Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer.
March 2016, Annals of surgery,
U Metzger, and U Laffer, and P Aeberhard, and M Arigoni, and S Arma, and J Barras, and R Egeli, and S Martinoli, and W Mueller, and W Schweizer
Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer.
December 1996, Journal of clinical gastroenterology,
U Metzger, and U Laffer, and P Aeberhard, and M Arigoni, and S Arma, and J Barras, and R Egeli, and S Martinoli, and W Mueller, and W Schweizer
Randomized Controlled Trial of the Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer.
December 2017, Annals of surgery,
U Metzger, and U Laffer, and P Aeberhard, and M Arigoni, and S Arma, and J Barras, and R Egeli, and S Martinoli, and W Mueller, and W Schweizer
Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial.
March 2002, Langenbeck's archives of surgery,
U Metzger, and U Laffer, and P Aeberhard, and M Arigoni, and S Arma, and J Barras, and R Egeli, and S Martinoli, and W Mueller, and W Schweizer
[Early adjuvant intraportal chemotherapy after hepatectomy for metastases of colorectal origin].
May 1986, Journal de chirurgie,
Copied contents to your clipboard!